These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 1438709

  • 1. Protection against metastasis of radiation-induced thymic lymphosarcoma and weight loss in C57Bl/6NCr1BR mice by an autoclave-resistant factor present in soybeans.
    Evans SM, Van Winkle T, Szuhaj B, Michel KE, Kennedy AR.
    Radiat Res; 1992 Nov; 132(2):259-62. PubMed ID: 1438709
    [Abstract] [Full Text] [Related]

  • 2. Cancer prevention by protease inhibitors.
    Kennedy AR.
    Prev Med; 1993 Sep; 22(5):796-811. PubMed ID: 8234219
    [Abstract] [Full Text] [Related]

  • 3. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
    Kennedy AR, Szuhaj BF, Newberne PM, Billings PC.
    Nutr Cancer; 1993 Sep; 19(3):281-302. PubMed ID: 8346077
    [Abstract] [Full Text] [Related]

  • 4. Studies related to the potential antigenicity of the Bowman-Birk inhibitor, an anticarcinogenic protease inhibitor isolated from soybeans.
    Maki PA, Paterson Y, Kennedy AR.
    Nutr Cancer; 1994 Sep; 22(2):185-93. PubMed ID: 14502847
    [Abstract] [Full Text] [Related]

  • 5. Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.
    Wan XS, Serota DG, Ware JH, Crowell JA, Kennedy AR.
    Nutr Cancer; 2002 Sep; 43(2):167-73. PubMed ID: 12588697
    [Abstract] [Full Text] [Related]

  • 6. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
    Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL.
    Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
    [Abstract] [Full Text] [Related]

  • 7. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.
    Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL.
    Clin Cancer Res; 2000 Dec; 6(12):4684-91. PubMed ID: 11156220
    [Abstract] [Full Text] [Related]

  • 8. Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum.
    Kennedy CW, Donahue JJ, Wan XS.
    Nutr Cancer; 1996 Dec; 26(2):209-17. PubMed ID: 8875558
    [Abstract] [Full Text] [Related]

  • 9. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor.
    St Clair WH, Billings PC, Carew JA, Keller-McGandy C, Newberne P, Kennedy AR.
    Cancer Res; 1990 Feb 01; 50(3):580-6. PubMed ID: 2297699
    [Abstract] [Full Text] [Related]

  • 10. Restoration of connexin 43 by Bowman-Birk protease inhibitor in M5076 bearing mice.
    Suzuki K, Yano T, Sadzuka Y, Sugiyama T, Seki T, Asano R.
    Oncol Rep; 2005 Jun 01; 13(6):1247-50. PubMed ID: 15870950
    [Abstract] [Full Text] [Related]

  • 11. Oncogenicity evaluations of chemopreventive soy components in p53((+/-)) (p53 knockout) mice.
    Johnson WD, Dooley L, Morrissey RL, Arp L, Kapetanovic I, Crowell JA, McCormick DL.
    Int J Toxicol; 2006 Jun 01; 25(3):219-28. PubMed ID: 16717037
    [Abstract] [Full Text] [Related]

  • 12. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor.
    Kennedy AR, Beazer-Barclay Y, Kinzler KW, Newberne PM.
    Cancer Res; 1996 Feb 15; 56(4):679-82. PubMed ID: 8630994
    [Abstract] [Full Text] [Related]

  • 13. Imbibition of soybean seeds in warm water results in the release of copious amounts of Bowman-Birk protease inhibitor, a putative anticarcinogenic agent.
    Palavalli MH, Natarajan SS, Wang TT, Krishnan HB.
    J Agric Food Chem; 2012 Mar 28; 60(12):3135-43. PubMed ID: 22372424
    [Abstract] [Full Text] [Related]

  • 14. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1994 Jan 28; 424():1-304. PubMed ID: 12616287
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 28; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 18. Cationized Bowman-Birk protease inhibitor as a targeted cancer chemopreventive agent.
    Ekrami H, Kennedy AR, Witschi H, Shen WC.
    J Drug Target; 1993 Sep 28; 1(1):41-9. PubMed ID: 8069543
    [Abstract] [Full Text] [Related]

  • 19. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
    Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL.
    Cancer Epidemiol Biomarkers Prev; 2000 Jan 28; 9(1):43-7. PubMed ID: 10667462
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.